Hi Iam up early to, Just reading what info I can get on this company. Do you guys think that there will be some big plays on this stock as far as price goes in the near future? Seems that way to me I just wanted your opinions on that. Thanks
Re: Earnings Are In
Mipo is best understood as a "proof of platform" to big pharma and secondarily a effective medicine to a slice of a market. Revenue is truly a secondary consideration even if our partner wasnt controlly the distribution. That deal and EU approval raised more attention among experts than revenue but also freed SC and team to broaden the scope of P2 and now P3 initiatives. Those moves over the past 24 months have further widened big pharma interest. The recent interviews and presentations have one clear message, the ISiS AS platform is real and flexible in targeting important proteins and effective beyond expectations when the ISIS team presses forward.
For hockey fans think "shots on goal" for the ISIS team versus other midcap biotechs as Kramer would say. A validated platform with multiple initiatives attracts even more expert attention in every pharma firm. The stock buzz is great but the real value now is in the buzz within the strategic initiatives divisions of companies reviewing their own gaps in pipeline drugs. New delivery methods deepen that interest in key areas, too.
This is a bad time to sell because it is obvious to all of us long time ISIS investors that the "rocket has cleared the tower" and is accelerating.
No better time to be an ISIS long. Ignore short term blips